GREY:ATBPF - Post by User
Comment by
MasterAlgaeon Sep 25, 2020 8:31am
220 Views
Post# 31619078
RE:New Coverage?
RE:New Coverage? Antibe Therapeutics initiated with a Buy at Maxim Maxim analyst Jason McCarthy initiated coverage of Antibe Therapeutics with a Buy rating and C$1 price target. The analyst notes that the company's lead product Otenaproxesul - being developed to treat osteoarthritis of the knee - has a "significant opportunity" as a better NSAID and could also target the chronic pain market. McCarthy adds that the last two NSAIDs that went for reduced gastrointestinal issues generated $1B in first-year sales.
Read more at:
https://thefly.com/n.php?id=3165278
It came out yesterday morning:
Maxim analyst Jason McCarthy
Read more at:
https://thefly.com/n.php?id=3165278
https://thefly.com/landingPageNews.php?id=3165278&headline=ATBPF-Antibe-Therapeutics-initiated-with-a-Buy-at-Maxim
Antibe Therapeutics initiated with a Buy at Maxim Maxim analyst Jason McCarthy initiated coverage of Antibe Therapeutics with a Buy rating and C$1 price target. The analyst notes that the company's lead product Otenaproxesul - being developed to treat osteoarthritis of the knee - has a "significant opportunity" as a better NSAID and could also target the chronic pain market. McCarthy adds that the last two NSAIDs that went for reduced gastrointestinal issues generated $1B in first-year sales.
Read more at:
https://thefly.com/n.php?id=3165278